Re: Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates: author's response
Clin Microbiol Infect. 2024 Dec 21:S1198-743X(24)00598-6.
doi: 10.1016/j.cmi.2024.12.012.
Online ahead of print.
1 Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland; Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
2 Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
3 Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland. Electronic address: laurent.poirel@unifr.ch.